What is Enliven Therapeutics Inc's earnings per share (EPS)?

Enliven Therapeutics Inc (ELVN) reported diluted earnings per share of $-1.83 for fiscal year 2025. This represents a 3.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Enliven Therapeutics Inc Financials

ELVN

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Enliven Therapeutics Inc (ELVN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ELVN FY2025 2026-05-07

Enliven operates as an equity-funded drug developer, with cash burn driven by research spending rather than capital investment.

By FY2025, operating cash burn was -$70.3M while free cash flow was nearly the same at -$70.5M, showing the loss is being spent in the lab and organization rather than in heavy equipment. That matters because net losses widened over the past three fiscal years, yet FY2025 was still funded mainly by $218.9M of financing inflow, so outside capital — not internal cash generation — is the funding engine.

In FY2025, R&D spending of $85.9M was more than double SG&A at $33.8M, which tells you the cost base is still centered on advancing the pipeline rather than supporting a selling organization. That spending pattern means the pace of development, not sales volume, is the main driver of expenses.

The balance sheet flipped from negative equity in FY2022 to large positive equity thereafter, meaning operating runway has been extended mainly through new equity capital rather than debt. You can see the trade-off in shares outstanding, which rose from 41.3M in FY2023 to 59.4M in FY2025 as the company funded itself through equity rather than leverage.

Financial Health Signals

Financial Profile 33/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Enliven Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

100

Enliven Therapeutics Inc carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

100

With a current ratio of 28.66, Enliven Therapeutics Inc holds $28.66 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Returns

Enliven Therapeutics Inc generates a -22.6% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -28.7% the prior year.

Piotroski F-Score Weak

3/9

Enliven Therapeutics Inc passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.68x

For every $1 of reported earnings, Enliven Therapeutics Inc generates $0.68 in operating cash flow (-$70.3M OCF vs -$103.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$119.4M

YoY-14.5%

Enliven Therapeutics Inc's EBITDA was -$119.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 14.5% from the prior year.

Net Income

-$103.7M

YoY-16.5%

Enliven Therapeutics Inc reported -$103.7M in net income in fiscal year 2025. This represents a decrease of 16.5% from the prior year.

EPS (Diluted)

$-1.83

YoY+3.2%

Enliven Therapeutics Inc earned $-1.83 per diluted share (EPS) in fiscal year 2025. This represents an increase of 3.2% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$70.5M

YoY+3.8%

Enliven Therapeutics Inc generated -$70.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 3.8% from the prior year.

Cash & Debt

$98.9M

YoY-20.3%

5Y CAGR+15.7%

Enliven Therapeutics Inc held $98.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

59M

YoY+21.5%

Enliven Therapeutics Inc had 59M shares outstanding in fiscal year 2025. This represents an increase of 21.5% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-22.6%

YoY+6.2pp

Enliven Therapeutics Inc's ROE was -22.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 6.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$85.9M

YoY+6.3%

5Y CAGR+21.7%

Enliven Therapeutics Inc invested $85.9M in research and development in fiscal year 2025. This represents an increase of 6.3% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$158K

YoY+259.1%

5Y CAGR+54.4%

Enliven Therapeutics Inc invested $158K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 259.1% from the prior year.

ELVN Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$85.9M+6.3%	$80.8M+25.1%	$64.6M+108.2%	$31.0M+51.5%	$20.5M-36.3%	$32.2M
SG&A Expenses	$33.8M+42.2%	$23.8M+25.4%	$19.0M+144.0%	$7.8M+81.2%	$4.3M-55.1%	$9.5M
Operating Income	-$119.7M-14.4%	-$104.6M-25.2%	-$83.5M-115.3%	-$38.8M-56.7%	-$24.8M+40.6%	-$41.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0-100.0%	$232K	$0	$0	N/A	N/A
Net Income	-$103.7M-16.5%	-$89.0M-24.3%	-$71.6M-90.1%	-$37.7M-52.2%	-$24.7M+40.2%	-$41.4M
EPS (Diluted)	$-1.83+3.2%	$-1.89+6.0%	$-2.01+83.3%	$-12.05	$-10.73	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$20.7M	N/A	$18.2M-15.2%	$21.5M-13.7%	$24.9M	N/A	$21.3M+12.9%	$18.8M
SG&A Expenses	$7.1M	N/A	$6.9M-3.1%	$7.1M+4.3%	$6.8M	N/A	$5.8M+0.6%	$5.8M
Operating Income	-$27.8M	N/A	-$25.1M+12.2%	-$28.6M+9.8%	-$31.7M	N/A	-$27.1M-10.0%	-$24.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	$0	$0	N/A	N/A	$0-100.0%	$232K
Net Income	-$23.6M	N/A	-$20.1M+20.5%	-$25.3M+11.2%	-$28.5M	N/A	-$23.2M-16.1%	-$19.9M
EPS (Diluted)	$-0.38	N/A	$-0.32+34.7%	$-0.49+14.0%	$-0.57	N/A	$-0.48-17.1%	$-0.41

ELVN Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$476.2M+46.2%	$325.8M+19.8%	$271.9M+226.4%	$83.3M-26.5%	$113.3M+24.8%	$90.8M
Current Assets	$474.9M+49.3%	$318.1M+19.5%	$266.2M+242.3%	$77.8M-29.7%	$110.7M+22.4%	$90.4M
Cash & Equivalents	$98.9M-20.3%	$124.1M+23.9%	$100.1M+32.6%	$75.5M-31.3%	$110.0M+130.7%	$47.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$16.6M+4.1%	$15.9M-38.7%	$26.0M-83.8%	$160.1M+2.5%	$156.2M+40.6%	$111.1M
Current Liabilities	$16.6M+4.1%	$15.9M-38.5%	$25.9M+166.5%	$9.7M+68.9%	$5.8M-7.9%	$6.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$459.6M+48.3%	$309.8M+26.0%	$245.9M+420.1%	-$76.8M-79.1%	-$42.9M-111.2%	-$20.3M
Retained Earnings	-$347.2M-42.6%	-$243.5M-57.6%	-$154.4M-86.4%	-$82.9M-83.3%	-$45.2M+53.0%	-$96.1M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$464.9M-2.4%	$476.2M-3.0%	$490.9M-2.6%	$503.9M+66.5%	$302.6M-7.1%	$325.8M+6.7%	$305.4M-6.6%	$327.0M
Current Assets	$463.1M-2.5%	$474.9M-1.6%	$482.7M-2.6%	$495.6M+68.4%	$294.3M-7.5%	$318.1M+7.1%	$297.0M-6.6%	$318.1M
Cash & Equivalents	$132.2M+33.7%	$98.9M-2.8%	$101.7M-14.8%	$119.4M+17.4%	$101.7M-18.1%	$124.1M+23.4%	$100.6M+3.9%	$96.9M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.5M-30.7%	$16.6M+12.3%	$14.8M-4.3%	$15.4M+8.0%	$14.3M-10.3%	$15.9M-6.5%	$17.0M-23.0%	$22.1M
Current Liabilities	$11.5M-30.7%	$16.6M+13.1%	$14.7M-3.7%	$15.2M+8.9%	$14.0M-12.2%	$15.9M-6.5%	$17.0M-23.0%	$22.1M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$453.4M-1.4%	$459.6M-3.5%	$476.1M-2.5%	$488.5M+69.4%	$288.3M-7.0%	$309.8M+7.4%	$288.4M-5.4%	$304.9M
Retained Earnings	-$370.8M-6.8%	-$347.2M-9.3%	-$317.5M-6.8%	-$297.4M-9.3%	-$272.0M-11.7%	-$243.5M-10.5%	-$220.3M-11.7%	-$197.1M

ELVN Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$70.3M+3.9%	-$73.2M-19.5%	-$61.3M-91.0%	-$32.1M-67.6%	-$19.1M+48.8%	-$37.4M
Capital Expenditures	$158K+259.1%	$44K-70.5%	$149K-75.7%	$612K+220.4%	$191K+961.1%	$18K
Free Cash Flow	-$70.5M+3.8%	-$73.2M-19.2%	-$61.4M-87.9%	-$32.7M-69.2%	-$19.3M+48.4%	-$37.4M
Investing Cash Flow	-$173.8M-382.9%	-$36.0M+75.7%	-$148.4M-24150.3%	-$612K-220.4%	-$191K+98.9%	-$16.7M
Financing Cash Flow	$218.9M+64.4%	$133.2M-43.2%	$234.3M+13123.1%	-$1.8M-77.1%	-$1.0M-101.0%	$96.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$19.3M-21.8%	-$15.8M-19.3%	-$13.3M+22.1%	-$17.1M+29.3%	-$24.1M-40.2%	-$17.2M-41.1%	-$12.2M+40.3%	-$20.4M
Capital Expenditures	$0	$0+100.0%	-$1K-100.7%	$139K+595.0%	$20K	$0-100.0%	$22K+1000.0%	$2K
Free Cash Flow	-$19.3M-21.8%	-$15.8M-19.3%	-$13.3M+22.8%	-$17.2M+28.8%	-$24.1M-40.4%	-$17.2M-40.8%	-$12.2M+40.2%	-$20.4M
Investing Cash Flow	$42.5M+243.5%	$12.4M+405.1%	-$4.1M+97.8%	-$183.6M-12965.4%	$1.4M+96.3%	$727K-95.1%	$14.8M+144.0%	-$33.7M
Financing Cash Flow	$10.1M+1513.6%	$623K+269.3%	-$368K-100.2%	$218.4M+93223.9%	$234K-99.4%	$40.0M+3478.5%	$1.1M-38.2%	$1.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

ELVN Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-22.6%+6.2pp	-28.7%+0.4pp	-29.1%	N/A	N/A	N/A
Return on Assets	-21.8%+5.5pp	-27.3%-1.0pp	-26.3%+18.9pp	-45.2%-23.4pp	-21.8%+23.7pp	-45.5%
Current Ratio	28.66+8.7	19.99+9.7	10.28+2.3	8.00-11.2	19.24+4.8	14.47
Debt-to-Equity	0.04-0.0	0.05-0.1	0.11+2.2	-2.08+1.6	-3.64+1.8	-5.47
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-5.2%	N/A	-4.2%+1.0pp	-5.2%+4.7pp	-9.9%	N/A	-8.0%-1.5pp	-6.5%
Return on Assets	-5.1%	N/A	-4.1%+0.9pp	-5.0%+4.4pp	-9.4%	N/A	-7.6%-1.5pp	-6.1%
Current Ratio	40.32+11.7	28.66-4.3	32.95+0.4	32.58+11.5	21.06+1.1	19.99+2.5	17.44+3.1	14.39
Debt-to-Equity	0.03-0.0	0.040.0	0.030.0	0.03-0.0	0.050.0	0.050.0	0.06-0.0	0.07
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Dianthus Therapeutics Inc DNTH

$4.7B

Nuvation Bio Inc NUVB

$1.6B

Zymeworks ZYME

$1.9B

Intellia Therape NTLA

$1.8B

Arcus Bioscience RCUS

$3.0B

Frequently Asked Questions

Is Enliven Therapeutics Inc profitable?

No, Enliven Therapeutics Inc (ELVN) reported a net income of -$103.7M in fiscal year 2025.

What is Enliven Therapeutics Inc's EBITDA?

Enliven Therapeutics Inc (ELVN) had EBITDA of -$119.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Enliven Therapeutics Inc's return on equity (ROE)?

Enliven Therapeutics Inc (ELVN) has a return on equity of -22.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Enliven Therapeutics Inc's free cash flow?

Enliven Therapeutics Inc (ELVN) generated -$70.5M in free cash flow during fiscal year 2025. This represents a 3.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Enliven Therapeutics Inc's operating cash flow?

Enliven Therapeutics Inc (ELVN) generated -$70.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Enliven Therapeutics Inc's total assets?

Enliven Therapeutics Inc (ELVN) had $476.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Enliven Therapeutics Inc's capital expenditures?

Enliven Therapeutics Inc (ELVN) invested $158K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Enliven Therapeutics Inc spend on research and development?

Enliven Therapeutics Inc (ELVN) invested $85.9M in research and development during fiscal year 2025.

How many shares does Enliven Therapeutics Inc have outstanding?

Enliven Therapeutics Inc (ELVN) had 59M shares outstanding as of fiscal year 2025.

What is Enliven Therapeutics Inc's current ratio?

Enliven Therapeutics Inc (ELVN) had a current ratio of 28.66 as of fiscal year 2025, which is generally considered healthy.

What is Enliven Therapeutics Inc's debt-to-equity ratio?

Enliven Therapeutics Inc (ELVN) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Enliven Therapeutics Inc's return on assets (ROA)?

Enliven Therapeutics Inc (ELVN) had a return on assets of -21.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Enliven Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Enliven Therapeutics Inc (ELVN) had $98.9M in cash against an annual operating cash burn of $70.3M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Enliven Therapeutics Inc's Piotroski F-Score?

Enliven Therapeutics Inc (ELVN) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Enliven Therapeutics Inc's earnings high quality?

Enliven Therapeutics Inc (ELVN) has an earnings quality ratio of 0.68x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Enliven Therapeutics Inc?

Enliven Therapeutics Inc (ELVN) scores 33 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.